

3FV



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Steven H. Olson et al.

Serial No.: 10/697,547 (Case No. 21102DA)

Filed: October 30, 2003

Art Unit: 1626

Entitled: 11-BETA HYDROXYSTEROID
DEHYDROGENASE 1 INHIBITORS USEFUL
FOR THE TREATMENT OF DIABETES AND
DYSLIPIDEMIA

Examiner: K. A. Saeed

Assistant Commissioner for Patents
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT AND
AMENDMENT UNDER 37 C.F.R. § 1.111

Sir:

In response to the Official action of March 24, 2006, for which a reply is due by April 24, 2006, the Applicants respectfully request reconsideration of the application in view of the following amendments and remarks. Any additional fees associated with the Response may be charged to Merck Deposit Account No. 13-2755.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this response.

Remarks begin on page 9 of this response.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450, on the date appearing below.

By [Signature] Date 4-19-06
MERCK & CO., INC.